The Hodgkins Lymphoma Treatment market involves drugs and therapies used for treating Hodgkin's lymphoma. Hodgkin's lymphoma is a type of lymphoma, which is a cancer that starts in the white blood cells called lymphocytes. This cancer usually involves the lymph nodes and spreads from one node or group of lymph nodes to another. The major treatment strategies for Hodgkins lymphoma include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy uses drugs to destroy cancer cells and usually involves a combination of drugs given in cycles. Radiation therapy uses high-energy rays or particles to destroy cancer cells and shrink tumors. Targeted therapy uses drugs or other substances to identify and attack specific cancer cells.
The Global Hodgkins Lymphoma Treatment Market is estimated to be valued at US$ 0.68 Mn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in The Hodgkins Lymphoma Treatment are Medtronic PLC, ICU Medical, Inc., Viggo Medical Devices, Teleflex Incorporated, Olympus America, Polymedicure, Ambu A/S., Verathon Inc., SourceMark, SunMed, KARL STORZ, Flexicare (Group) Limited, and Vyaire Medical. These players are engaged in developing and marketing drugs and therapies for effective Hodgkins lymphoma treatment.
The increasing prevalence of Hodgkin's lymphoma worldwide is driving the demand for treatment. As per the statistics by Cancer Research U.K, over 1700 new cases of Hodgkin's lymphoma are reported annually in the UK. The rising cases are prompting the development of innovative and targeted treatment options.
The key players are actively expanding their global footprint through mergers & acquisitions and collaboration activities. For instance, in October 2022, Medtronic acquired Affera, expanding its transplant portfolio with an AI-enabled monitoring platform for detecting early signs of organ rejection. This kind of strategic initiatives are helping the industry grow on a global scale.
Market drivers
The increasing healthcare expenditure globally is a major driver of this market. As per the statistics by World Bank, the global healthcare spending grew at an annual average rate of 5.4% between 2000 to 2019 and was estimated at $8.3 trillion in 2019. The rising healthcare investments by both governments and individuals are enabling improved access to sophisticated Hodgkins lymphoma treatment options. This is expected to propel the demand during the forecast period.
The current geopolitical tensions between various countries are impacting the Hodgkins Lymphoma Treatment market growth. Political instability and economic sanctions in some regions are hindering healthcare infrastructure development and availability of advanced treatment options. This is reducing patients' access to quality lymphoma care. With rising global conflicts and tensions, healthcare resource allocation towards cancer treatment is also getting impacted. This can negatively influence the Hodgkins Lymphoma Treatment market size during the forecast period.
To ensure sustained market expansion, manufacturers must diversify their supply networks and consider alternate sourcing and manufacturing hubs that are more politically stable. They also need to focus on relatively neutral nations with growing healthcare expenditures. Partnerships with local healthcare providers in developing countries can help increase the affordability and availability of treatment modalities in such regions. Further, collaborations with global NGOs can help expand outreach in areas facing significant geopolitical issues. Adopting such strategies will help make lymphoma therapies more accessible globally and counter supply chain disruptions due to regional political instability.
In terms of geographical revenue distribution, North America currently captures the largest share of the global Hodgkins Lymphoma Treatment market, led by the strong healthcare sector and presence of major industry players in the US. However, Asia Pacific is emerging as the fastest growing regional market, driven by China, India, Japan, and other Southeast Asian countries. This is attributed to improving medical infrastructure, rising healthcare spending, increasing cancer incidence, and growing medical tourism in the region. Governments are also supporting diagnosis and treatment of various cancers including Hodgkins Lymphoma.
The Middle Eastern and African markets are also expected to witness steady growth during the forecast period due to initiatives towards enhancing early cancer detection rates and making available modern treatment methods to combat cancer related mortality rates. However, political instability in certain countries may pose challenges for market participants.
Development of low-cost alternative treatment options and partnerships with regional hospitals and research institutions can help boost Hodgkins Lymphoma Treatment uptake in emerging countries and lower-income regions more effectively. This will open newer growth avenues for market players over the coming years.
Get more insights on Hodgkin's lymphoma treatment market
The overall non-hodgnins lymphoma treatment market size was regarded at USD 11.7 billion out of 2018 and is relied upon to create at a CAGR of 9.5% over the assessed period.
The creating take-up of premium-esteemed things like safe assigned spot inhibitors, Keytruda, and Opdivo is driving the market.
Likewise, the dispatch of a few novel treatments and name expansion of popularized items are required to support the development.
For example, in 2018, the U.S. FDA supported Adcetris for use in patients with a high-level phase of traditional Hodgkin lymphoma in blend with chemotherapy.
As indicated by Leukemia and Lymphoma Society, in 2019, 82,310 new instances of lymphoma and 8,110 and 74,200 instances of Hodgkin and Non-Hodgkin Lymphoma (NHL), separately, are relied upon to be analysed in the U.S.
In addition, it is assessed that there are 874,730 individuals going away or are living with lymphoma in the U.S.
